SCHEMBL2326735

SCHEMBL2326735

COC(=O)c1cc(-c2ccccc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.57
ALAD P13716 2/20 0.51
ABL1 P00519 1/20 0.51
MMP12 P39900 6/20 0.50
ALDH1A1 P00352 4/20 0.49
HPGD P15428 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
PRKCZ Q05513 1/20 0.49
TSHR P16473 1/20 0.46
DGAT1 O75907 1/20 0.46
GAA P10253 2/20 0.45
EGFR P00533 1/20 0.45
MAPT P10636 1/20 0.45
MMP13 P45452 2/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
LDHA P00338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882926 0.85 ALAD (0.50) HDAC6ALADABL1MMP12ALDH1A1
SCHEMBL26681320 0.84 HSD17B1 (0.56) HDAC6ALADABL1MMP12HSD17B1
SCHEMBL505511 0.83 ALAD (0.70) HDAC6ALADMMP12MEN1KMT2A
SCHEMBL6369543 0.83 ALAD (0.49) HDAC6ALADABL1MMP12ALDH1A1
SCHEMBL6368361 0.83 ALAD (0.71) HDAC6ALADABL1MMP12ALDH1A1
SCHEMBL6704697 0.83 ALAD (0.71) ALADABL1ALDH1A1MAPT
SCHEMBL6881198 0.83 OPRD1 (0.56) ALADABL1MMP12ALDH1A1LMNA
SCHEMBL6664021 0.83 MMP12 (0.51) HDAC6ALADABL1MMP12ALDH1A1
SCHEMBL6882390 0.83 ABL1 (0.52) HDAC6ALADABL1ALDH1A1HPGD
SCHEMBL31117930 0.83 ABL1 (0.52) HDAC6ALADABL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 US disclosed
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-05-08 US disclosed
CN-119923385-A Inhibitors of RNA helicase DHX9 and uses thereof 埃克森特治疗公司 2025-05-02 CN disclosed
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-02-25 US disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2024-12-10 US disclosed
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-09-26 US disclosed
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-08-22 US disclosed
US-9567465-B2 Thiophene azo carboxylate dyes and laundry care compositions containing the same MILLIKEN & COMPANY (US) 2017-02-14 US disclosed
US-9556337-B2 Thiophene azo dyes and laundry care compositions containing the same MILLIKEN & COMPANY (US) 2017-01-31 US disclosed
EP-2354134-B1 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR ASTELLAS PHARMA INC (JP) 2016-02-24 EP disclosed
CN-102239164-B 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC 2013-10-30 CN disclosed
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
CN-102239164-A 2h-chromene compound and derivative thereof ASTELLAS PHARMA INC 2011-11-09 CN disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
EP-2354134-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF Astellas Pharma Inc. (JP) 2011-08-10 EP disclosed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B HDAC6 1055/4885ALAD 1485/4885ABL1 3028/4885
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HDAC6 1220/4885ALAD 2081/4885ABL1 2926/4885
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 HDAC6 4352/4885ALAD 4788/4885ABL1 3649/4885
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B HDAC6 1047/4885ALAD 1951/4885ABL1 3007/4885
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B HDAC6 1055/4885ALAD 1485/4885ABL1 3028/4885
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B HDAC6 1047/4885ALAD 1951/4885ABL1 3007/4885
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 HDAC6 611/4885ALAD 3624/4885ABL1 2800/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 HDAC6 4140/4885ALAD 4870/4885ABL1 2636/4885
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HDAC6 1220/4885ALAD 2081/4885ABL1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.